Loading…
Reported covered position: Leg. Assistant to Sen. Jay Rockefeller 1991-97
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - tax issues, including as contained in S. America's Healthy Future Act of 2009 Internal and industry discussions
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - tax issues, including as contained in S. America's Healthy Future Act of 2009 Internal and industry discussions
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · second_quarter · 2A
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
Cross-retaliation threat in US-Brazil cotton subsidy dispute
Source: Senate LDA
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR3590, S 1796 and related bills and amendments - tax issues, including those as contained in S. America's Healthy Future Act of 2009
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding Patent reform and intellectual property issues, including issues surrounding patent settlements HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding follow-on biologics/pathway for biosimilar pharmaceuticals
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding Patent reform and intellectual property issues, including issues surrounding patent settlements HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding follow-on biologics/pathway for biosimilar pharmaceuticals
Community-Based Mental Health Infrastructure Improvements Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
Community-Based Mental Health Infrastructure Improvements Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1796, and related bills and amendments - Tax Issues, including those contained within health care reform legislation Tariff legislation (currently unassigned)
America's Healthy Future Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1796, and related bills and amendments - Patent Reform and Intellectual Property issues, including issues surrounding patent settlements HR 3590, S 1796, and related bills and amendments - Follow-on biologics/pathway for biosimilar pharmaceuticals
Physician Payments Sunshine Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
Physician Payments Sunshine Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Health Care Reform S.301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Discuss Patient Assistance Programs Issues regarding disclosure of drug sample data Independent Drug Education and Outreach Act - Academic Detailing issues VA/DoD regarding TRICARE retail rebate legislation Veterans Health Care Budget Reform and Transparency Act Discussions regarding global access to medicines
Physician Payments Sunshine Act of 2009
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1796, and related bills and amendments - Tax Issues, including those contained within health care reform legislation Tariff legislation (currently unassigned)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1796, and related bills and amendments - Patent Reform and Intellectual Property issues, including issues surrounding patent settlements HR 3590, S 1796, and related bills and amendments - Follow-on biologics/pathway for biosimilar pharmaceuticals
Access to Life-Saving Medicine Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Preserve Access to Affordable Generics Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Preserve Access to Affordable Generics Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Protecting Consumer Access to Generic Drugs Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Protecting Consumer Access to Generic Drugs Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Pathway for Biosimilars Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries HR 5629, Pathway for Biosimilars Act Intellectual property provisions of free-trade agreements and otherwise as part of US trade policy
Pathway for Biosimilars Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Pathway for Biosimilars Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries HR 5629, Pathway for Biosimilars Act Intellectual property provisions of free-trade agreements and otherwise as part of US trade policy
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencis that do not harm innovative industries-US Senate Patent settlements (reverse payments) legislation-US House/US Senate Regarding intellectual property issues
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Patent Reform Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
Biologics Price Competition and Innovation Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Physician Payments Sunshine Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage S.2029 - Physician Payments Sunshine Act of 2007; Grassley/Kohl Bill - regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis DoD Tricare issues, including retail pharmacy rebate and other issues Comparative Effectivensss - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement Genetic Information Nondiscrimination Act Information regarding company patient assistance program Health care reform Legislation to fund cancer research, cancer supportive services and improve access to coverage 340B program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Pulmonary and Cardiac Rehabilitation Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Pulmonary and Cardiac Rehabilitation Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Mental Health Parity Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Mental Health Parity Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage S.2029 - Physician Payments Sunshine Act of 2007; Grassley/Kohl Bill - regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis DoD Tricare issues, including retail pharmacy rebate and other issues Comparative Effectivensss - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement Genetic Information Nondiscrimination Act Information regarding company patient assistance program Health care reform Legislation to fund cancer research, cancer supportive services and improve access to coverage 340B program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Mental Health Parity Act of 2007
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
H.R.3590, S.1796 and related bills and amendments - tax issues, including as contained in S. America's Healthy Future Act of 2009 Internal and industry discussions
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · second_quarter · Q2
H.R.3590, S.1796 and related bills and amendments - tax issues, including as contained in S. America's Healthy Future Act of 2009 Internal and industry discussions
Cross-retaliation threat in US-Brazil cotton subsidy dispute
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · first_quarter · Q1
HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding Patent reform and intellectual property issues, including issues surrounding patent settlements HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding follow-on biologics/pathway for biosimilar pharmaceuticals
Cross-retaliation threat in US-Brazil cotton subsidy dispute Market access issues (currently unassigned)
HR3590, S 1796 and related bills and amendments - tax issues, including those as contained in S. America's Healthy Future Act of 2009
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · fourth_quarter · Q4
HR 3590, S 1796, and related bills and amendments - Tax Issues, including those contained within health care reform legislation Tariff legislation (currently unassigned)
HR 3590, S 1796, and related bills and amendments - Patent Reform and Intellectual Property issues, including issues surrounding patent settlements HR 3590, S 1796, and related bills and amendments - Follow-on biologics/pathway for biosimilar pharmaceuticals
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · third_quarter · Q3
Patent settlements (reverse payments) legislation Patent reform and intellectual property issues Follow-on biologics legislation
Tax issues, including as contained in S. America's Healthy Future Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · first_quarter · 1A
International trade issues, including free-trade agreements and negotiations Import Safety
Tax issues, including economic stimulus legislation, repatriaion and deferral, and bilateral tax issues
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · second_quarter · Q2
Health Care Reform S.301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Discuss Patient Assistance Programs Issues regarding disclosure of drug sample data Independent Drug Education and Outreach Act - Academic Detailing issues VA/DoD regarding TRICARE retail rebate legislation Veterans Health Care Budget Reform and Transparency Act Discussions regarding global access to medicines
Tax issues, including international tax proposals and health care financing
Patent Reform and Intellectual Property Issues Patent settlements (reverse payments) legislation Follow-on biologics legislation
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · first_quarter · Q1
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
Tax issues, including economic stimulus legislation, repatriaion and deferral, and bilateral tax issues
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · third_quarter · 3A
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
Discussion of tax issues, including extension of the Research and Development Tax Credit, and bilateral US-UK tax issues
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · fourth_quarter · Q4
International trade issues, including free-trade agreements, with Members and Staff-US House/US Senate Import Safety - internal discussions
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencis that do not harm innovative industries-US Senate Patent settlements (reverse payments) legislation-US House/US Senate Regarding intellectual property issues
Tax issues, including economic stimulus legislation, and bilateral US-UK tax issues
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · third_quarter · Q3
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
Discussion of international trade issues, including free-trade agreements, with Members and Staff-US House/US Senate
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · second_quarter · Q2
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage S.2029 - Physician Payments Sunshine Act of 2007; Grassley/Kohl Bill - regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis DoD Tricare issues, including retail pharmacy rebate and other issues Comparative Effectivensss - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement Genetic Information Nondiscrimination Act Information regarding company patient assistance program Health care reform Legislation to fund cancer research, cancer supportive services and improve access to coverage 340B program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Tax issues, including extension of the Research and Development Tax Credit and bilateral US-UK tax issues
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · first_quarter · 1A
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · first_quarter · Q1
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Customs and Border Patrol issues surrounding data collection for maritime imports to US (10+2) International trade issues, including free-trade agreements and negotiations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics
International trade issues, including free-trade agreements and negotiations Import Safety
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Discussion of international trade issues, including free-trade agreements, with Members and Staff-US House/US Senate
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Discussion of tax issues, including extension of the Research and Development Tax Credit, and bilateral US-UK tax issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
International trade issues, including free-trade agreements Import Safety
S.1145, The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries HR 5629, Pathway for Biosimilars Act Intellectual property provisions of free-trade agreements and otherwise as part of US trade policy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office